Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974092 | 0.87 | CA1 (0.46) | PTGS2ALDH1A1CA12CA1CA2 | |
| SCHEMBL16914702 | 0.83 | PTGS2 (0.38) | PTGS2PTGS1ALDH1A1CA12CA1 | |
| SCHEMBL18242951 | 0.81 | ALDH1A1 (0.39) | PTGS2PTGS1ALDH1A1CA12CA1 | |
| SCHEMBL18242953 | 0.79 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1CA12CA1 | |
| SCHEMBL15507450 | 0.77 | ALDH1A1 (0.46) | PTGS2PTGS1ALDH1A1HSD17B10 | |
| SCHEMBL8712167 | 0.77 | LMNA (0.40) | PTGS2PTGS1ALDH1A1CA12CA1 | |
| SCHEMBL4418157 | 0.77 | ADRA2A (0.41) | PTGS2PTGS1ALDH1A1CA12CA1 | |
| SCHEMBL417312 | 0.77 | ALDH1A1 (0.53) | PTGS2PTGS1ALDH1A1CA12CA1 | |
| SCHEMBL27281565 | 0.77 | ALDH1A1 (0.53) | PTGS2PTGS1ALDH1A1CA12CA1 | |
| SCHEMBL997657 | 0.77 | ALDH1A1 (0.40) | ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799784-B2 | Quinoxaline derivatives of alpha-2 adrenergic agonists | NICOX S.A. (FR) | 2010-09-21 | — | — | US | disclosed |
| US-20080318965-A1 | Derivatives of Alpha2-Adrenergic Receptor Agonist | NICOX S.A. (FR) | 2008-12-25 | — | — | US | disclosed |
| US-20080318965-A1 | Derivatives of Alpha2-Adrenergic Receptor Agonist | NICOX S.A. (FR) | 2008-12-25 | — | — | US | disclosed |
| EP-1981852-A1 | NITROOXY-COMPRISING DERIVATIVES OF APRACLONIDINE AND BRIMODNIDINE AS AL PHA2 -ADRENERGIC RECEPTOR AGONISTS | NicOx S.A. (FR) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007090793-A1 | NITROOXY-COMPRISING DERIVATIVES OF APRACLONIDINE AND BRIMODNIDINE AS AL PHA2 -ADRENERGIC RECEPTOR AGONISTS | NICOX S.A. (FR) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318965-A1 | Derivatives of Alpha2-Adrenergic Receptor Agonist | ADRB2, ADRA2A, ADRB1 | PTGS2 146/4885PTGS1 297/4885ALDH1A1 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.